Cardiovascular Safety of Hydroxychloroquine-Azithromycin in 424 COVID-19 Patients

被引:2
|
作者
Million, Matthieu [1 ,2 ]
Lagier, Jean-Christophe [1 ,2 ]
Hourdain, Jerome [3 ,4 ]
Franceschi, Frederic [3 ,4 ]
Deharo, Jean-Claude [3 ,4 ]
Parola, Philippe [1 ,5 ]
Brouqui, Philippe [1 ,2 ]
机构
[1] IHU Mediterranee Infect, F-13005 Marseille, France
[2] Aix Marseille Univ, AP HM, Fac Sci Med & Paramed, Inst Rech Dev,Unite MEPHI Microbes Evolut Phylogen, F-13005 Marseille, France
[3] Ctr Hosp Univ Timone, AP HM, Serv Cardiol, F-13005 Marseille, France
[4] Aix Marseille Univ, Fac Sci Med & Paramed, C2VN, F-13005 Marseille, France
[5] Aix Marseille Univ, AP HM, Fac Sci Med & Paramed, VITROME,IRD, F-13005 Marseille, France
来源
MEDICINA-LITHUANIA | 2023年 / 59卷 / 05期
关键词
COVID-19; SARS-CoV-2; hydroxychloroquine; azithromycin; QTc interval; cardiac rhythm; safety; torsades de pointe; COMBINATION; THERAPY;
D O I
10.3390/medicina59050863
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Hydroxychloroquine (HCQ) combined with azithromycin (AZM) has been widely administered to patients with COVID-19 despite scientific controversies. In particular, the potential of prolong cardiac repolarization when using this combination has been discussed. Materials and Methods: We report a pragmatic and simple safety approach which we implemented among the first patients treated for COVID-19 in our center in early 2020. Treatment contraindications were the presence of severe structural or electrical heart disease, baseline corrected QT interval (QTc) > 500 ms, hypokalemia, or other drugs prolonging QTc that could not be interrupted. Electrocardiogram and QTc was evaluated at admission and re-evaluated after 48 h of the initial prescription. Results: Among the 424 consecutive adult patients (mean age 46.3 +/- 16.1 years; 216 women), 21.5% patients were followed in conventional wards and 78.5% in a day-care unit. A total of 11 patients (2.6%) had contraindications to the HCQ-AZ combination. In the remaining 413 treated patients, there were no arrhythmic events in any patient during the 10-day treatment regimen. QTc was slightly but statistically significantly prolonged by 3.75 +/- 25.4 ms after 2 days of treatment (p = 0.003). QTc prolongation was particularly observed in female outpatients <65 years old without cardiovascular disease. Ten patients (2.4%) developed QTc prolongation > 60 ms, and none had QTc > 500 ms. Conclusions: This report does not aim to contribute to knowledge of the efficacy of treating COVID-19 with HCQ-AZ. However, it shows that a simple initial assessment of patient medical history, electrocardiogram (ECG), and kalemia identifies contraindicated patients and enables the safe treatment of COVID-19 patients with HCQ-AZ. QT-prolonging anti-infective drugs can be used safely in acute life-threatening infections, provided that a strict protocol and close collaboration between infectious disease specialists and rhythmologists are applied.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Hydroxychloroquine and azithromycin use in COVID-19 era and cardiovascular concerns: Current perspective
    Kapoor, Aditya
    Sahu, Ankit Kumar
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2021, 7 (01) : 78 - 82
  • [22] Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy
    Scherrmann, J. M.
    AAPS JOURNAL, 2020, 22 (04):
  • [23] Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy
    JM. Scherrmann
    The AAPS Journal, 22
  • [24] Hydroxychloroquine and Azithromycin Combination in the Management of COVID-19 Infection: Safety and Effectiveness Challenges
    Abou Warda, Ahmed E.
    Tammam, Mahmoud
    El-Gazar, Rabab A.
    Sarhan, Rania M.
    Gaber, Sayed
    CURRENT DRUG SAFETY, 2022, 17 (02) : 143 - 151
  • [25] Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
    Megarbane, Bruno
    Scherrmann, Jean-Michel
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (07): : 808 - 814
  • [26] COVID-19 AND QTC: IS HYDROXYCHLOROQUINE WORTH THE RISK? A REVIEW OF QT PROLONGATION IN HOSPITALISED COVID-19 PATIENTS TREATED WITH HYDROXYCHLOROQUINE AND AZITHROMYCIN
    Pollock, A.
    Kumar, R.
    Devitt, P.
    Kent, B.
    Daly, C.
    HEART, 2020, 106 : A1 - A1
  • [27] Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19
    O'Connell, Thomas F.
    Bradley, Christopher J.
    Abbas, Amr E.
    Williamson, Brian D.
    Rusia, Akash
    Tawney, Adam M.
    Gaines, Rick
    Schott, Jason
    Dmitrienko, Alex
    Haines, David E.
    JACC-CLINICAL ELECTROPHYSIOLOGY, 2021, 7 (01) : 16 - 25
  • [28] Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection
    Giaime, Philippe
    Guenoun, Maxime
    Pedinielli, Nathalie
    Narbonne, Herve
    Bergounioux, Jean-Philippe
    Solas, Caroline
    Guilhaumou, Romain
    Sampol, Jerome
    Ollier, Jacques
    Sichez, Helene
    Serveaux, Marianne
    Brunner, Flora
    Bataille, Stanislas
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (08) : 1346 - 1353
  • [29] Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19
    Lauriola, Marinella
    Pani, Arianna
    Ippoliti, Giovanbattista
    Mortara, Andrea
    Milighetti, Stefano
    Mazen, Marjieh
    Perseghin, Gianluca
    Pastori, Daniele
    Grosso, Paolo
    Scaglione, Francesco
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (06): : 1071 - 1076
  • [30] Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients
    Garcia-Fernandez, Amaya
    Ramos-Ruiz, Pablo
    Ibanez-Criado, Alicia
    Moreno-Perez, Oscar
    Cambra-Poveda, Cristina
    Gabriel Martinez-Martinez, Juan
    REVISTA ESPANOLA DE CARDIOLOGIA, 2021, 74 (01): : 108 - 111